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Massimiliano Mancini, MD,* Vincenzo Petrozza, MD,† Andrea Cossarizza, MD, Pietro Gallo, MD,*
Robert W. Taylor, PHD,# Giulia d’Amati, MD, PHD*
Rome, Florence, and Modena, Italy; and Newcastle upon Tyne, United Kingdom
Objectives The purpose of this study was to clarify the molecular mechanisms linking human mitochondrial deoxyribonu-
cleic acid (mtDNA) dysfunction to cardiac remodeling.
Background Defects of the mitochondrial genome cause a heterogeneous group of clinical disorders, including mitochondrial
cardiomyopathies (MIC). The molecular events linking mtDNA defects to cardiac remodeling are unknown. En-
ergy derangements and increase of mitochondrial-derived reactive oxygen species (ROS) could both play a role
in the development of cardiac dysfunction in MIC. In addition, mitochondrial proliferation could interfere with
sarcomere alignment and contraction.
Methods We performed a detailed morphologic and molecular analysis on failing hearts from 3 patients with MIC, failing
human hearts due to ischemic heart disease (IHD) or dilated cardiomyopathies (DCM), and nonfailing hearts.
Results The MIC hearts showed marked mitochondrial proliferation with myofibril displacement. Consistent with morpho-
logic features, increase in mtDNA content per cell and induction of genes involved in mitochondrial biogenesis,
fatty acid metabolism, and glucose transport were observed. Down-regulation of these genes characterized DCM
and IHD hearts. A pronounced increase in mitochondrial-derived ROS was observed in MIC hearts compared with
failing hearts due to other causes. This was paralleled by up-regulation of genes encoding for uncoupling pro-
teins and antioxidant enzymes. However, there was not a significant increase in antioxidant enzyme activity.
Conclusions Our results suggest that besides energy deficiency, mitochondrial biogenesis per se is a maladaptive response in
MIC and, possibly, in other metabolic cardiomyopathies. (J Am Coll Cardiol 2007;50:1362–9) © 2007 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.06.035m
s
h
f
(
m
t
H
d
s
l
f
i
b
hutations in human mitochondrial deoxyribonucleic acid
mtDNA) cause a large variety of multi-system disorders
hose main unifying feature is the altered energy homeosta-
is (i.e., reduced adenosine triphosphate [ATP] produc-
ion). Highly energy-dependent tissues, such as the central
ervous system and skeletal and cardiac muscle, are com-
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ccepted June 3, 2007.only involved (1). Cardiac dysfunction can occur as the
ole or predominant symptom and often takes the form of
ypertrophic cardiomyopathy (2).
Previous studies from our group identified 2 unrelated
amilies with isolated maternally inherited cardiomyopathy
MIC) with a hypertrophic phenotype due to a homoplas-
ic point mutation (4300AG) in the mitochondrial
ransfer ribonucleic acid isoleucine (mt-tRNAIle) gene (3).
eart tissue from affected family members showed a severe
efect in respiratory chain enzyme activity and low steady-
tate levels of the mature mt-tRNAIle. Of note, comparably
ow levels of tRNAIle were present in skeletal muscle, which
ailed to show either a biochemical or a clinical defect. The
llness had an early onset and an adverse clinical course in
oth families, with rapid progression of left ventricular
ypertrophy to dilation and cardiac failure, necessitating
eart transplant in 2 patients.
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1363JACC Vol. 50, No. 14, 2007 Sebastiani et al.
October 2, 2007:1362–9 Mitochondrial Biogenesis and CardiomyopathyThe molecular events linking mtDNA defects to cardiac
ypertrophy are unknown. Studies of experimental models
uggest that both energy derangements and increase of
itochondrial-derived reactive oxygen species (ROS) could
lay a role in the development of cardiac dysfunction in
ICs (4,5). In addition, mitochondrial proliferation, a well
ecognized compensatory mechanism in mitochondrial dis-
ase, could contribute to cardiomyopathic remodeling
hrough mechanical dysfunction (6).
To better clarify the molecular mechanisms linking mtDNA
utations to cardiac hypertrophy and failure, we performed a
etailed morphologic and molecular analysis on failing hearts
rom 3 patients with tRNAIle mutation-related MIC, compar-
ng gene expression profiles of key regulators of mitochon-
rial biogenesis and cardiac energy metabolism to failing
uman hearts due to other causes and to nonfailing hearts.
n addition, we evaluated myocardial oxidative stress by
ssessing myocardial superoxide production, and gene ex-
ression and activity of the antioxidant enzymes mitochon-
rial manganese superoxide dismutase (MnSOD) and glu-
athione peroxidase (GPX).
ethods
atients. All studies conformed to Sapienza, University of
ome, Ethical Committee protocols.
The clinical profile of the 2 families with MIC has been
eported previously (3). After informed consent of relatives
in the case of autopsy samples) or patients, myocardial
issue was obtained within 2 h from death (Family #1,
atient #1) or heart transplant (Family #2, Patients #2 and
3) (3). In addition, samples from patients with end-stage
eart failure secondary to idiopathic dilated cardiomyopathy
DCM) (n  4) or ischemic heart disease (IHD) (n  9),
n whom metabolic disorders (including diabetes) were
xcluded on the basis of clinical records, were obtained at
eart transplant. Nonfailing (NF) heart samples were ob-
ained from donor hearts which were unsuitable for trans-
lantation for technical reasons (n 4) and within 2 h from
eath in pediatric patients who died for noncardiac causes in
hom mitochondrial disease was excluded on the basis of
istologic, histochemical, and respiratory chain enzyme
tudies (n  4). Clinical characteristics of the 3 groups are
eported in Table 1.
Clinical Characteristics of Patients and Molecul
Table 1 Clinical Characteristics of Patients
NF
(n  8)
M/F 4/4
Age, yrs (range) 21 (1 month–44)
LVEF, % NA
ANF/rRNA 18S 1.06 0.007
MHC-/rRNA 18S 1.20 0.04
MHC-/rRNA 18S 1.20 0.05
Gene expression data are mean  SEM.
ANF  atrial natriuretic factor; DCM  dilated cardiomyopathy; IHD  isch
myosin heavy chain; MIC  maternally inherited (mitochondrial) cardiomyopissue sample preparation.
mmediately after explant, mul-
iple samples of myocardial tis-
ue were snap-frozen in liquid
itrogen-chilled isopentane for
olecular and biochemical studies.
or histologic analysis, tissue sec-
ions obtained from formalin-fixed
araffin-embedded samples were
tained with hematoxylin and eo-
in, Masson trichrome, and peri-
dic acid Schiff  diastase. Ultra-
tructural studies were performed
n samples fixed in 4% parafor-
aldehyde-phosphate– buffered
aline and post-fixed in osmium
etroxide. Thin sections were
tained with uracyl acetate and
ead citrate and examined with a
M10 Philips (Eindhoven, the
etherlands) electron microscope.
uantitative real-time polymer-
se chain reaction. EVALUATION
F MTDNA COPY NUMBER. To-
al DNA from left ventricular
yocardial tissue was extracted
y phenol-chloroform standard
rocedures. The mtDNA content
as measured by quantitative real-
ime polymerase chain reaction
PCR) assays using a previously
escribed method (7). Briefly, an
tDNA fragment (nt 4625 to
714) and a nuclear DNA frag-
ent (FasL gene) were coampli-
ed by multiplex PCR using Taq-
an probe system and Platinum
uantitative PCR SuperMix-UDG (Invitrogen, Life Tech-
ologies, Paisley, United Kingdom). The PCR conditions,
rimers, and probes are as previously detailed (7). A standard
urve for mtDNA and nuclear DNA was generated using serial
nown dilutions of a vector (provided by Genemore, Modena,
taly) in which the regions used as template for the 2 ampli-
Abbreviations
and Acronyms
ANF  atrial natriuretic
factor
DCM  dilated
cardiomyopathy
GLUT  glucose
transporter
GPX  glutathione
peroxidase
IHD  ischemic heart
disease
mCPT-I  carnitine
palmitoyl transferase
muscle isoform
MIC  maternally inherited
cardiomyopathy
MnSOD  manganese
superoxide dismutase
mtDNA  mitochondrial
deoxyribonucleic acid
mt-tRNAIle  mitochondrial
transfer ribonucleic acid
isoleucine
NADPH  nicotinamide
adenine dinucleotide
3-phosphate
PCR  polymerase chain
reaction
PGC  peroxisome
proliferator activated
receptor  coactivator
PPAR  peroxisome
proliferator activated
receptor
Tfam  transcription and
mitochondrial DNA
maintenance factor
arkers of Cardiac Hypertrophy
olecular Markers of Cardiac Hypertrophy
MIC
 3)
DCM
(n  4)
IHD
(n  9)
3/0 4/0 6/3
(5–26) 45 (33–48) 59 (45–67)
 4.04 23 4.6 26 7.2
 1.92 11.93 4.45 10.83 1.92
 0.01 0.03 0.01 0.06 0.02
 0.01 0.05 0.01 0.46 0.05emic heart disease; LVEF  left ventricular ejection fracti
athy; NF  nonfailing; rRNA  ribosomal ribonucleic acidar M
and M
(n
18
12
8.95
0.06
0.05on; MHC 
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Mitochondrial Biogenesis and Cardiomyopathy October 2, 2007:1362–9cations were cloned tail to tail to have a ratio of 1:1 of the
eference molecules.
ENE EXPRESSION. The relative expression of the following
enes was evaluated: atrial natriuretic factor (ANF) and
yosin heavy chain  and  isoforms, as molecular markers
f cardiac hypertrophy; peroxisome proliferator activated
eceptor (PPAR)-, a critical regulator of cardiac oxidative
etabolism, along with 3 of its targets, carnitine palmitoyl
ransferase muscle isoform (mCPT-I) and medium- and
ong-chain acyl-CoA dehydrogenase; PPAR- coactivator
 (PGC-1), nuclear respiratory factor 1 and 2 (NRF1
nd NRF2), and transcription and mtDNA maintenance
actor (Tfam), important regulators of mitochondrial bio-
enesis; along with PGC-1, a known homologue of
GC-1; the glucose transporter isoforms (GLUT1 and
LUT4); heart isoforms of uncoupling protein (UCP2 and
CP3); and antioxidant enzymes MnSOD and GPX.
Total ribonucleic acid (RNA) was isolated from left
entricular myocardial tissue by using Trizol reagent and
easured with NanoDrop ND-1000 spectrophotometer
NanoDrop Technologies, Wilmington, Delaware). One
icrogram of total RNA was reverse-transcribed to cDNA
sing random hexamer primers (AMV Reverse Transcrip-
ase, Promega, Madison, Wisconsin). Relative expression of
ach gene was determined by quantitative real-time PCR
sing the Platinum SYBR Green qPCR SuperMix-UDG
Invitrogen).
For each target gene, primers were carefully designed
ith Beacon Designer Software (Bio-Rad, Hercules, Cali-
ornia) and checked by using Blast software (National
enter for Biotechnology Information, Bethesda, Mary-
and) to avoid cross-homology. The specificity of the am-
licons was confirmed by direct sequencing using an ABI
rism 310 Genetic analyzer (Applied Biosystems, Foster
ity, California) following standard procedures. Nucleotide
equences for the primers are given in Table 2.
Quantitative real-time PCR was performed in triplicate
sing 1 l cDNA template in a 50-l reaction. Linearity
nd efficiency of PCR amplifications were assessed using
tandard curves generated by serial dilution of cDNA; in
ddition, melt curve analysis was used to confirm the
pecificity of amplification and absence of primer dimers. In
ll samples, the relative expression of each target gene with
espect to 1 NF control (reference sample) was evaluated
ith the comparative threshold cycle (Ct) method, as
escribed in the User Bulletin for the RelQuant UpDate
Bio-Rad). All values were normalized to the 18S rRNA
ousekeeping gene. Quantification was carried out with
Cycler IQ Optical System Software (Bio-Rad).
easurement of superoxide production by lucigenin
hemiluminescence. Superoxide (O2
) production was
easured by lucigenin-enhanced chemiluminescence (8).
riefly, myocardial tissue was homogenized in ice-cold 20
mol/l Tris HCl, pH 7.4, containing 10 g/ml leupeptin,0 g/ml aprotinin, 0.2 mmol/l phenylmethanesulpho- cylfluoride, and phosphatase inhibitor cocktail (Sigma-
ldrich, Milan, Italy). After spinning for 10 min at 3,000
pm at 4°C, protein concentration was measured by bicin-
honinic acid protein assay (Pierce, Rockford, Illinois).
xperiments were performed on a luminometer (Lumat LB
507, EG&G Berthold, Bundoora, Australia) using 100 g
rotein/tube and a nonredox-cycling dose of lucigenin (5
mol/l), which previous reports have indicated as a sensitive
nd valid probe for superoxide detection (8). Superoxide
eneration was measured both in the absence of substrate
nd in presence of 300 mol/l nicotinamide adenine dinu-
rimer Sequences
Table 2 Primer Sequences
Gene Sequence
rRNA18S F: 5=-CCAGTAAGTGCGGGTCATAAGC-3=
R: 5=-AACCATCCAATCGGTAGTAGCG-3=
ANF F:5=-CAACGCAGACCTGATGGATTTC-3=
R:5=-GCTTCTTCATTCGGCTCACTG-3=
MHC- F: 5=-GAAGGGATAACCAGGGGAAGC-3=
R: 5=-CGGGCACGAAGCACTCAG-3=
MHC- F: 5=-TTCCTCATCTGTAGACACACTTG-3=
R: 5=-TAGCCGCTCCTTCTCTGAC-3=
GPX F: 5=-GTAGTGCTGGACAGTGACAACC-3=
R: 5=-ATATTTGGAGGCAGTGGGAGATG-3=
MnSOD F: 5=-AAACCTCAGCCCTAACGG-3=
R: 5=-GCAGCAATTTGTAAGTGTCC-3=
PGC-1 F: 5=-ACACAGTCGCAGTCACAACAC-3=
R: 5=-GGAGTGGTGGGTGGAGTTAGG-3=
PGC-1 F: 5=GCACCTCACCTCGGCACAG-3=
R: 5=CGGCTCCTTGTCCTCCTTGG-3=
NRF1 R: 5=-GTAACCCTGATGGCACTGTCTC-3=
F: 5=-GCTTGCGTCGTCTGGATGG-3=
NRF2 F: 5=-TTCCTTCAGCAGCATCCTCTCC-3=
R: 5=-AATCTGTGTTGACTGTGGCATCTG-3=
Tfam F: 5=-AACAACGAAAATATGGTGCTGAGG-3=
R: 5=-CAAGTATTATGCTGGCAGAAGTCC-3=
PPAR- F: 5=-GGTCATCCTCTCAGGAAAGG-3=
R: 5=-ACTGTCATCCAGTTCCAGTG-3=
GLUT1 F: 5=-TGCTGCTCAGTGTCATCTTCATCC-3=
R: 5=-GCCGACCCTCTTCTTTCATCTCC-3=
GLUT4 F: 5=-GCTACCTCTACATCATCCAGAATCTC-3=
R: 5=-CCAGAAACATCGGCCCA-3=
LCAD F: 5=-AAGTGATGTTGTGATTGTAGTTG-3=
R: 5=-GAATAGTTCTGCGGTATCCTG-3=
MCAD F: 5=-AATTAGTGAAGAATTGGCTTATGG-3=
R: 5=-ACATCAATGGCTCCTCAGTC-3=
mCPT-I F: 5=-TCCTTCCAACTCACATTCAG-3=
R: 5=-GGTGTCTGTCTCCTCTCC-3=
UCP2 F: 5=-GACACGGTCCAGGAGTTC-3=
R: 5=-CTCTGTGCTTGAAGTCTGAC-3=
UCP3 F: 5=-TTTGCTGACCTCGTTACCTTTCC-3=
R: 5=-GTCTGGACCGCCTGGTTCTC-3=
LUT  glucose transporter; GPX  glutathione peroxidase; LCAD  long-chain acyl-CoA dehydro-
enase; MCAD  medium-chain acyl-CoA dehydrogenase; mCPT-I  carnitine palmitoyl trans-
erase muscle isoform; MnSOD  manganese superoxide dismutase; NRF  nuclear respiratory
actor; PGC  peroxisome proliferator activated receptor  coactivator; PPAR  peroxisome
roliferator activated receptor; Tfam  transcription and mitochondrial deoxyribonucleic acid
aintenance factor; UCP  uncoupling protein; other abbreviations as in Table 1.leotide 3-phosphate (NADPH) or 5 mmol/l succinic acid.
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October 2, 2007:1362–9 Mitochondrial Biogenesis and Cardiomyopathyo confirm that the measured signal was attributable to O2
,
cell-permeable superoxide scavenger, 4,5-dihydroxy-1,3-
enzene-disulfonic acid (Tiron, Sigma-Aldrich, 20 mmol/l),
as used. In a subset of experiments, samples were prein-
ubated with the following agents to assess potential sources
f O2
 production: diphenyleneiodonium 20 mol/l), a
avoprotein inhibitor the blocks NADPH oxidase; N-
itro-L-arginine methyl ester hydrochloride (100 mol/l), a
itric oxide synthase inhibitor; rotenone (50 mol/l), a
pecific inhibitor of mitochondrial respiratory chain com-
lex I; and oxypurinol (100 mol/l), an inhibitor of xan-
hine oxidase. A buffer blank was subtracted from each
eading. Light emission was recorded and expressed as mean
ight units/s per mg of homogenate protein over 10 min.
uperoxide dismutase and glutathione peroxidase activity
ssays. For measurement of SOD and GPX activity, myo-
ardial tissue was homogenized in 20 mmol/l HEPES, pH
.2, containing 1 mmol/l EDTA, 210 mmol/l mannitol,
nd 70 mmol/l sucrose, sonicated, and centrifuged at 14,000
pm for 20 min at 4°C. Total SOD activity was measured on
he supernatant by the Chemical Superoxide Dismutase
ssay kit (Cayman Chemical, Ann Arbor, Michigan). This
ses a tetrazolium salt for the detection of O2
 radicals
enerated by xanthine oxidase and hypoxanthine. The SOD
ctivity was expressed as units per mg of protein. One unit
f SOD is defined as the amount of enzyme needed to
btain 50% dismutation of O2
 radical. Specific MnSOD
ctivity was measured by the addition of 5 mmol/l potas-
ium cyanide to the tissue sample to inhibit the cytosolic
opper-zinc (CuZn) SOD. The GPX activity was expressed
s nanomoles of reduced NADP converted to oxidized
ADP per minute per milligram of protein, as previously
escribed (9).
tatistical analyses. All data are expressed as mean 
EM. Gene expression data are expressed using a natural
ogarithmic scale to reduce the different variability among
roups and to help with their graphical representation.
nalysis of variance (ANOVA) test accounting for different
ariability among groups followed by multiple pairwise
omparison adjusted with the Bonferroni corrections, was
erformed. Standard ANOVA procedures were performed
n enzyme activities data. Results were considered to be
ignificant at p  0.05. All of the reported p values are
djusted by Bonferroni correction based on 6 multiple
omparisons. Statistical computing has been performed by
he Statistical Software R (package nmle, Wirtschaftsuni-
ersität, Wien, Austria).
esults
orphologic analyses. Histologic analysis of paraffin sec-
ions from MIC hearts revealed cardiac myocyte hypertro-
hy associated with prominent perinuclear vacuolization
Fig. 1A). The vacuoles contained inhomogeneous granular
aterial that stained with periodic acid Schiff and wasigested by diastase, suggesting the presence of glycogen pFig. 1B). Ultrastructural analysis confirmed this finding
Fig. 1C), revealing mitochondrial proliferation causing
isplacement of myofibrils (Fig. 1D).
ene expression profile. ANF AND MYOSIN HEAVY CHAIN
SOFORMS. The messenger RNA level of ANF was in-
reased 10-fold in the 3 groups of failing hearts (FH)
ompared with control samples. In contrast, all FH showed
dramatic decrease of transcript levels of MHC- (up to
0-fold decrease) and MHC- (up to 25-fold decrease)
Table 1). These data are consistent with the previous
bservation of reduced myofilament content in FH (10).
TDNA CONTENT AND GENES INVOLVED IN MITOCHON-
RIAL BIOGENESIS. As shown in Figure 2A, the mtDNA
ontent per cell increased in MIC compared with both controls
nd FH of other causes. The transcript levels of several key
egulators of mitochondrial biogenesis (PGC1-, NRF1,
RF2, and Tfam) were coordinately up-regulated (15-fold
ncrease) in MIC and down-regulated in DCM and IHD
earts (Fig. 2B). Interestingly, a similar increase in mtDNA
mount, along with induction of genes involved in mitochon-
rial biogenesis, was observed in skeletal muscle from 2 MIC
atients (Family #1, Patients #2 and #3; data not shown),
espite the lack of morphologic features of mitochondrial
Figure 1 Histologic and Ultrastructural Analysis of
Maternally Inherited Mitochondrial Cardiomyopathy
(A) Left ventricular section obtained from a 23-year-old patient (patient 3). Car-
diac myocyte hypertrophy is associated with prominent perinuclear vacuoliza-
tion (hematoxylin and eosin, 	20). (B) The vacuoles contain granular material
that stains with periodic acid Schiff (arrows, 	40). (C) Ultrastructural analysis
reveals patchy areas characterized by absence of myofibrils and accumulation
of osmiophilic granular and fibrillar material consistent with glycogen (uracyl
acetate lead citrate, 	3,150). (D) Proliferation of polymorphic mitochondria
causes displacement of sarcomere. Note a giant mitochondria (arrow; uracyl
acetate lead citrate, 	5,000).roliferation (as previously reported [3]). As discussed previ-
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Mitochondrial Biogenesis and Cardiomyopathy October 2, 2007:1362–9usly, this is intriguing, because the biochemical defect asso-
iated with the 4300AG mutation is not expressed in this
issue, despite a similar reduction in the steady-state levels of
RNAIle transcript (3).
The mRNA level of PGC-1 showed a modest, though
tatistically significant, increase both in MIC (2-fold in-
rease) and in IHD (1.5-fold increase) whereas it was
own-regulated in DCM compared with control samples
Fig. 2C).
EGULATORS OF FATTY ACID METABOLISM AND GLUCOSE
RANSPORT. Both PPAR- and its targets were up-
egulated in MIC compared with control samples (
10-
old increase), whereas they were down-regulated in
ailing DCM and IHD hearts (Fig. 2D). An increased
xpression of GLUT1 (6-fold increase) and GLUT4
16-fold increase) was observed in MIC compared with
ontrol samples. In contrast, GLUT1 was markedly
educed in DCM (10-fold decrease) and showed a slight
eduction in IHD (0.5-fold decrease), whereas GLUT4
howed only a slight decrease in DCM and IHD
Figure 2 mtDNA Amount and Expression of Genes
Involved in Mitochondrial Biogenesis and FAO
(A) The mitochondrial deoxyribonucleic acid (mtDNA) amount is significantly
increased in MIC compared with NF hearts. *p  0.001 versus NF, DCM, and
IHD. (B) The mRNA levels of PGC1-, NRF1, NRF2, and Tfam are coordinately
up-regulated in MIC and down-regulated in DCM and IHD. *p  0.001 versus
NF; †p  0.05 versus NF. (C) Expression levels of PGC1- are slightly in-
creased in MIC and IHD and decreased in DCM respect to NF. *Differences
between each group and all the others are statistically significant (p  0.001).
(D) Both PPAR- and its targets mCPT-I, MCAD, and LCAD are up-regulated in MIC
and down-regulated in DCM and IHD hearts. *p  0.001 versus NF; †p  0.01
versus NF. Yellow  NF; red  MIC; blue  DCM; green  IHD. DCM  dilated
cardiomyopathy; FAO  fatty acid oxidation; IHD  ischemic heart disease; LCAD
 long-chain acyl-CoA dehydrogenasey; MCAD  medium-chain acyl-CoA dehydro-
genase; mCPT-I  carnitine palmitoyl transferase muscle isoform; MIC  mater-
nally inherited cardiomyopath; NF  nonfailing; NRF  nuclear respiratory factor;
PGC  peroxisome proliferator activated receptor  coactivator; PPAR  peroxi-
some proliferator activated receptor; Tfam  transcription and mitochondrial
deoxyribonucleic acid maintenance factor.Fig. 3A).NCOUPLING PROTEINS. The expression of both cardiac
soforms UCP2 and UCP3 was up-regulated in MIC with
espect to controls (20- and 7-fold increases, respectively).
oth isoforms were down-regulated in DCM and IHD
ailing hearts, with UCP2 showing the lower amount
Fig. 3B).
yocardial O2
 production. Superoxide production was
inimal in myocardial homogenate from failing and non-
ailing hearts both in absence of substrates and in presence
f succinate (not shown). After the addition of NADPH,
2
 production raised significantly in all FH compared
ith control samples. However, this phenomenon was more
triking in MIC, with a 2-fold increase in O2
 production
ompared with DCM and IHD (Fig. 4A). Detection of
uperoxide was virtually abolished by Tiron.
To investigate the sources of O2
 production, experi-
ents were repeated in the presence of specific inhibitors of
otential ROS-generating enzymes. In all FH, O2
 gener-
tion was significantly decreased by diphenyleneiodonium,
onfirming the phagocyte-type NADPH oxidase as the
Figure 3 Expression of Glucose Transporters (GLUT1 and
GLUT4) and Uncoupling Proteins (UCP2 and UCP3)
(A) GLUT1 (orange) and GLUT4 (green) were up-regulated in mitochondrial car-
diomyopathy (MIC) compared with NF hearts; GLUT1 was markedly reduced in
DCM and slightly reduced in IHD compared with controls; GLUT4 shows a slight
reduction in DCM and IHD. *p  0.001 versus NF. (B) UCP2 (orange) and
UCP3 (green) were up-regulated in MIC compared with NF hearts. Both iso-
forms were down-regulated in DCM and IHD failing hearts, UCP2 showing the
lowest amount. *p  0.001 versus NF. Abbreviations as in Figure 2.
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October 2, 2007:1362–9 Mitochondrial Biogenesis and Cardiomyopathyajor source of O2
 in this setting (8). In addition, MIC
earts showed a significant decrease in O2
 production in
resence of rotenone, a specific inhibitor of mitochondrial
espiratory chain complex I and oxypurinol, an inhibitor of
anthine oxidase (Fig. 4B), whereas the presence of N-
itro-L-arginine methyl ester hydrochloride had no effect
not shown).
uperoxide dismutase and glutathione peroxidase gene
xpression and activity. Induction of both the MnSOD
15-fold increase) and GPX (5-fold increase) genes’
xpression was observed in MIC compared with controls.
owever, the activity of both enzymes did not show any
ignificant change in MIC hearts, despite a clear trend
oward an increase for GPX (Figs. 5B and 5C). The lack of
tatistically significant change in GPX activity may be due
o variability within the control groups.
In contrast to MIC, expression of both these genes was
lightly decreased in DCM and IHD hearts (Fig. 5A),
lthough only IHD hearts showed a significant reduction of
Figure 4 NADPH Oxidase-Dependent O2
 Production
Detected by Lucigenin Chemiluminescence
(A) Nicotinamide adenine dinucleotide 3-phosphate (NADPH)-dependent super-
oxide production is increased in all failing hearts compared with control sam-
ples. The increase is more striking in MIC. *p  0.05 versus NF; †p  0.001
versus NF; ‡p  0.001 versus DCM and IHD. (B) Effect of specific inhibitors of
enzymatic reactive oxygen species production or of the superoxide scavenger
Tiron. *p  0.05 versus baseline; †p  0.01 versus baseline. DPI  diphenyl-
eneiodonium; MLU  mean light units; other abbreviations as in Figure 2.PX activity (Figs. 5B and 5C).iscussion
merging evidence points to energy derangement as a major
ulprit for development of cardiac hypertrophy and progres-
ion to heart failure, both in acquired and in inherited
isease. In recent years, numerous studies using experimen-
al models of pressure overload and in human FH have
onsistently demonstrated a myocardial shift from fatty acid
xidation toward glucose oxidation for energy production
see Huss and Kelly [11] for a review). This metabolic
witch is associated with the down-regulation of genes
nvolved in mitochondrial biogenesis and fatty acid metab-
lism and is mediated by deactivation of the transcriptional
egulator PPAR- and its coactivator PGC-1 (10,12).
he increased reliance of hypertrophic myocytes on glyco-
ytic pathways is likely finalized to reduce oxygen consump-
ion; however, it may contribute to the progression of
ardiac disease, possibly creating a relative energy-deficient
tate.
Figure 5 Gene Expression and
Activity of Antioxidant Enzymes
(A) Both MnSOD and GPX mRNA levels are increased in MIC compared with NF
hearts. Expression of both genes is slightly reduced in DCM and IHD hearts.
*p  0.01 versus NF; †p  0.05 versus NF. Orange  MnSOD; green  GPX.
(B) MnSOD activity didn’t show any changes in MIC, DCM, and IHD compared
with control samples. (C) A significant reduction of GPX activity was observed
in IHD hearts. *p  0.01 versus NF. GPX  glutathione peroxidise; MnSOD 
manganese superoxide dismutase; other abbreviations as in Figure 2.
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Mitochondrial Biogenesis and Cardiomyopathy October 2, 2007:1362–9In the present study, we reveal that there is a specific
etabolic gene expression profile in a cardiomyopathy
aused by a significant derangement of the mitochondrial
nergy production pathway. In fact, we observed a marked
p-regulation of PPAR- and its coactivator PGC-1,
long with a slight increase in the expression of PGC-1.
ccordingly, we observed the induction of genes involved in
atty acid metabolism, glucose transport, and mitochondrial
iogenesis. This last change is consistent with a dramatic
ncrease in mtDNA content per cell, as well as with
istologic and ultrastructural features of marked mitochon-
rial proliferation. In contrast, down-regulation of the
PAR-/PGC-1 complex and their targets, as well as
educed expression of glucose transporters, was observed in
CM and IHD FH, confirming previous observations
10,12). Interestingly, the expression level of PGC-1
howed opposite behavior in DCM and IHD. These data
uggest that the 2 homologues are regulated by different
echanisms in cardiac myocytes, as reported for brown
dipose tissue (13).
The coordinated induction in bioenergetic gene expres-
ion observed in MIC is likely to represent a compensatory
esponse to energy deficiency. We previously demonstrated
global defect of oxidative phosphorylation (OXPHOS) in
IC hearts, with very low activities of respiratory chain
omplexes I and IV (both containing mtDNA-encoded
ubunits) (3). Increase of mitochondrial biogenesis (i.e., an
ncrease in mitochondrial mass and induction of OXPHOS
ene as well as enzymes of intermediary metabolism) is a
ell known phenomenon in mitochondrial disorders (14).
n skeletal muscle, mitochondrial proliferation has been
hown to partly compensate for the respiratory dysfunction
y maintaining overall ATP production (15); the his-
opathologic hallmark of this phenomenon is the presence
f an increased number of mitochondria, mostly in the
ubsarcolemmal region. However, in cardiac muscle, induc-
ion of mitochondrial biogenesis has been proposed as a
aladaptive response. In fact, cardiac-specific induction of
GC-1 in mice results in cardiac dysfunction with mor-
hologic features of myocyte mitochondrial proliferation
nd myofibrillar disorganization and loss. Intriguingly, both
itochondrial proliferation and cardiomyopathy are revers-
ble upon cessation of transgene expression (6). Our findings
arallel the features reported in that experimental model,
uggesting that mitochondrial proliferation is linked to
rogressive cardiac dysfunction also in the human heart.
he ultrastructural features of altered sarcomere alignment
uggest that mitochondrial proliferation per se may possibly
nterfere with contractile function; this phenomenon is
imited to cardiomyocytes: In fact, in patients’ skeletal
uscle, lack of morphologic evidence of mitochondrial
roliferation correlates with normal muscle function (3).
his observation opens new perspectives on the complex
ssue of tissue specificity of homoplasmic mitochondrial
utations (16). cAnother interesting result of the present study is the
bservation of a more pronounced increase in myocardial
OS production in MIC compared with DCM and IHD.
n experimental conditions, NADPH oxidase was a major
ource of ROS in all failing hearts, as previously reported
8,17). However, the present results implicate both the
itochondrial respiratory chain and xanthine oxidase as a
ource of excessive superoxide. Thus, mitochondrial dys-
unction may contribute to the increased oxidative stress
oth by mitochondrial-derived O2
 and by a reduction of
TP/adenosine monophosphate ratio, which in turn acti-
ates the xanthine oxidase pathways. A somewhat paradoxic
bservation in the present study relates to the observation of
igh levels of ROS in the presence of increased expression
f UCP2 and UCP3 in MIC. In fact, UCPs are expected to
issipate the proton electrochemical gradient formed during
itochondrial respiration and generate heat instead of
TP, thus reducing mitochondrial superoxide production
18). On the other hand, this mechanism may also lead to
n increase in mitochondrial oxygen consumption, thus
mplifying the energy dysfunction observed in MIC. We
ay speculate that the increase in UCP expression in MIC
s insufficient to decrease ROS production through the
echanism of uncoupling respiration, and, therefore, high
evels of ROS are maintained. Alternatively, recent studies
n adipose tissue and skeletal muscle suggest that UCPs are
egulated at post-translational level (19).
Increased ROS production in MIC was not reflected by
parallel induction of antioxidant enzyme activity, despite a
arked up-regulation of MnSOD and GPX genes. Similar
esults have been previously reported in human FH (20) and
n a mouse model of MIC (4) and support the hypothesis
hat end-stage heart muscle is unable to respond to oxidative
tress by adequately increasing antioxidant countermeasures.
We believe that the present results on increased ROS
roduction in MIC are of interest, because mounting
vidence has implicated ROS signaling in cardiac maladap-
ive remodeling (21). However, additional work is required
o fully address this issue.
A metabolic gene expression profile similar to MIC has
een reported in the cardiomyopathy that develops in the
ontext of diabetes (22,23). In that condition, increase of
irculating free fatty acids may lead to activation of PPAR-
/PGC-1 complex, which in turn causes induction of
itochondrial biogenesis and fatty acid oxidation. Further-
ore, induction of UCPs along with cardiac OXPHOS
ysfunction and increased oxidative stress has previously
een observed (24).
onclusions
he present results suggest that mitochondrial biogenesis is
maladaptive response in MIC and, possibly, in other
etabolic cardiomyopathies. Besides energy deficiency, me-hanical interference with sarcomere alignment and con-
t
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ion are possible detrimental factors to myocyte function.
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